Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Date:12/3/2009

SAN FRANCISCO, Dec. 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looki
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
(Date:3/30/2015)... and MADISON, Wis. , ... Shigehiro Nakajima ,) (TSE: 4901) ("Fujifilm") and Cellular Dynamics ... ICEL ) ("CDI"), a leading developer and manufacturer ... precise specifications, today announced that the two companies have ... CDI via an all-cash tender offer to be followed ...
(Date:3/27/2015)... 27, 2015 Earlier this year, the ... of hair regrowth in adult men and women with ... Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification of ... by products that over-promise and under-deliver, FDA Clearance underscores ... and confidence among more than 80 million men and ...
(Date:3/27/2015)... , March 27, 2015  Peter Walter was ... Science for his pioneering work on how proteins are ... of a regulatory mechanism that cells use to handle ... Walter is a professor of biochemistry at the University ... for treating a range of human diseases related to ...
Breaking Biology Technology:Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3
... Quantitation of siRNA Target Gene Expression , ... easiest , ways to confirm gene profiling ... methods such as array analysis and siRNA experiments, especially , ... For RT-PCR experiments, total RNA must be isolated first. ...
... , ... analysis , of microRNAs (miRNAs). Recently, we introduced the ... the mir Vana miRNA Labeling Kit , and ... miRNA function and identifying miRNA target sites (Pre-miR miRNA ...
... , Remove >90% of mammalian RNA from , ... Simple procedure takes less than 2 hours , ... Seamless integration with , MICROB Express ... Enables microarray expression analysis with , bacterial RNA isolated from host cells ...
Cached Biology Technology:Cells-to-cDNA II Applications 2Cells-to-cDNA II Applications 3Cells-to-cDNA II Applications 4Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 2Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 3Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 4Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 5Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 6Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 7Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform 8Bacterial RNA Isolation From Infected Eukaryotic Hosts 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 3Bacterial RNA Isolation From Infected Eukaryotic Hosts 4Bacterial RNA Isolation From Infected Eukaryotic Hosts 5Bacterial RNA Isolation From Infected Eukaryotic Hosts 6
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... a continued effort to eliminate the scourge of malaria ... State University-led research team will use a $9.1 million ... in the small, landlocked country. Terrie Taylor, an ... osteopathic physician, is leading the project, which aims to ...
... Imagine finding out before you leave the pediatrician,s office ... more serious requiring a different treatment. A novel ... could help primary-care physicians quickly and more accurately determine ... throat swab. Mark R. Hartman, a Cornell ...
... Spanish . Researchers at the University ... Cecilio and the University Rey Juan Carlos- have proven that ... improves within 24 hours after receiving a 30-minute massage. ... the population. This type of disorder is usually treated with ...
Cached Biology News:MSU researchers awarded $9.1 million grant to battle malaria in Malawi 2Instant testing for sore throats wins CIMIT prize 2Instant testing for sore throats wins CIMIT prize 3Instant testing for sore throats wins CIMIT prize 4
Extracti-Gel D Detergent Removing Gel...
... Thermocycler provides high speed and excellent temperature ... a TGradient Thermocycler can be run without ... a silver block for 48 or 96 ... plates or in-situ applications are available. The ...
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
... systems provide fast and reliable scalable ... proteomics and drug development laboratories. Staccato ... configurations; Mini Workstation Series, Application Series ... Staccato Application Series systems use a ...
Biology Products: